DexCom (NASDAQ:DXCM) Downgraded by StockNews.com to “Hold”

StockNews.com lowered shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research report report published on Saturday.

A number of other analysts have also weighed in on DXCM. Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Oppenheimer cut their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Barclays dropped their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Performance

DexCom stock opened at $69.00 on Friday. The company’s 50-day moving average price is $69.70 and its 200-day moving average price is $94.48. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market cap of $26.95 billion, a PE ratio of 41.32, a price-to-earnings-growth ratio of 2.16 and a beta of 1.17.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Taylor Frigon Capital Management LLC lifted its holdings in shares of DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares in the last quarter. Waters Parkerson & CO. LLC grew its position in DexCom by 4.2% during the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after buying an additional 10,892 shares in the last quarter. Legal & General Group Plc grew its position in DexCom by 1.7% during the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after buying an additional 49,076 shares in the last quarter. Factory Mutual Insurance Co. grew its position in DexCom by 136.1% during the third quarter. Factory Mutual Insurance Co. now owns 404,230 shares of the medical device company’s stock worth $27,100,000 after buying an additional 233,000 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in DexCom by 533.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 36,510 shares of the medical device company’s stock worth $4,140,000 after purchasing an additional 30,743 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.